Implementing preclinical study findings to protocol design: translational studies with alloreactive CTL for gliomas

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Recurrent gliomas pose significant treatment challenges.
• Previous pilot studies suggest potential survival benefits with adjuvant alloreactive cytotoxic T lymphocytes (alloCTL) therapy.
• Optimizing cellular therapy production and quality control is crucial for clinical application.

Purpose of the Study:

• To refine the production and standardization of alloCTL for a Phase I dose escalation trial in recurrent gliomas.
• To identify cost-effective methods for alloCTL expansion and quality control.
• To evaluate the impact of standard glioma therapeutics on alloCTL function.

Main Methods:

• Testing synthetic tissue culture media, including AIM-V, for alloCTL growth.
• Transitioning alloCTL production from artificial capillary systems to tissue culture bags.
• Establishing release criteria (≥60% CD3+, ≥60% viability) and quality control measures for alloCTL infusates.
• Determining optimal Interleukin-2 (IL-2) dosage and expiration time for alloCTL infusates.
• Phenotypic identification of alloCTL subsets (CD3+/CD8+/CD69+) and assessment of Interferon-gamma (IFN-γ) production.
• In vitro assessment of alloCTL cytotoxicity against glioma cells and evaluation of combined effects with temozolomide and bevacizumab.

Main Results:

• AIM-V medium was identified as superior for alloCTL growth.
• Standardized release criteria ensured consistent alloCTL cytotoxicity.
• 30,000 IU of IL-2 retained alloCTL viability and function for a 10-hour expiration period.
• A specific alloCTL subset (CD3+/CD8+/CD69+) showed upregulated IFN-γ production, indicating robust cytotoxic function.
• Temozolomide and bevacizumab did not adversely affect short-term alloCTL cytotoxic function.

Conclusions:

• Optimized production and quality control methods enhance the feasibility of alloCTL therapy for recurrent gliomas.
• The identified alloCTL subset may serve as a biomarker for treatment response.
• Combinatorial chemo-immunotherapy using alloCTL with temozolomide and bevacizumab warrants further investigation for glioma treatment.